AptarGroup Inc (ATR)

Aptar Releases 2025 Corporate Sustainability ReportJune 18, 2026 5:00 PM
Business WireAptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today released its 2025 Corporate Sustainability Report entitled Progress in Motion. The report highlights activities across Aptar’s global operations from January 1 through December 31, 2025, and summarizes certain milestones and progress measured across the company’s global sustainability strategy, which is focused on three key pillars:This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618316625/en/Aptar’s 2025 Corporate Sustainability ReportCare - operating with care for employees, communities and the environment by aiming to continuously improve our impact and seeking to reduce our footprint;Collaboration - innovating alongside customers, suppliers, industry coalitions and nonprofits to help enable progress toward their goals – as well as for better outcomes for people and our planet; andCircularity - aiming to help the industry advance system-scale change intended to benefit people today and for generations to come by addressing climate change and the waste crisis.“Aptar’s progress in 2025 reflects our belief that sustainability is integral to how we operate, innovate and create value. Across our business, we continued advancing efforts through Care, Collaboration and Circularity that support our employees and communities, strengthen partnerships, improve our operations and respond to evolving expectations from customers and stakeholders. I am proud of our employees around the world whose commitment and expertise continue to turn our sustainability priorities into meaningful progress,” said Stephan B. Tanda, Aptar President and CEO.Aptar has made progress advancing key areas of its global sustainability strategy. Highlights from Aptar’s Sustainability Report include:At year-end 2025, 98% of Aptar’s electricity was sourced from renewable sources. Following the power purchase agreements in Europe and North America for a more localized source of renewable energy dedicated to Aptar, the company continued to make progress towards its science-based targets.In the past year, Aptar completed a Corporate Sustainability Reporting Directive (CSRD) aligned double materiality assessment. This assessment is intended to help the company identify and prioritize the topics that matter in terms of the company’s impact on people and the planet, while also considering the financial risks and opportunities.Aptar continues to support employees and communities through safety, health and wellness programs, learning and development opportunities, donations and participation in local charitable events, including support for women’s economic empowerment and emergency campaigns through Aptar’s global signatory organization, CARE®.Innovation towards more sustainable products continues to drive our teams across the globe. Working to better understand the life cycle impacts of our products and innovate to deliver performance value through the value chain and product life cycle remains a global focus.“Sustainability at Aptar is about keeping progress in motion and advancing responsibly, even as expectations and challenges evolve. Through our sustainability strategy, we are working to strengthen our operations, support our people and communities, and partner across our value chain to drive meaningful change. We remain focused on making steady, measurable progress that reflects both our commitments and the realities of the systems we operate within,” said Beth Holland, Aptar’s Chief Sustainability Officer.Aptar’s 2025 Corporate Sustainability Report was prepared in accordance with the Global Reporting Initiative (GRI) Standards and obtained reasonable assurance from ERM CVS for our Scope 1 & 2 GHG Emissions and energy metrics. We also obtained limited assurance from ERM CVS for certain waste, water, product sustainability, and health and safety metrics. The complete assurance report can be found on digitally on the website.To minimize paper waste, Aptar encourages readers to view the 2025 Corporate Sustainability Report digitally on our website under the Sustainability Reporting Center.About AptarAptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at www.aptar.com.This press release contains forward-looking statements, including statements regarding our sustainability strategy, initiatives, goals, targets, anticipated progress, expected benefits and impacts, climate-related efforts, renewable electricity efforts, science-based targets, circularity initiatives, product sustainability efforts, collaborations, and employee and community-related initiatives. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could,” which are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: supplier participation, performance, transparency and data availability and accuracy; availability, cost and performance of renewable energy, lower-carbon materials, recycled materials and other alternatives; customer, consumer and stakeholder preferences and expectations; product performance, quality, sustainability, circularity or supply chain matters; the regulatory environment, including laws, regulations, standards, methodologies and reporting requirements relating to climate, emissions, renewable electricity, sustainability, product sustainability, waste, water, health and safety matters, and related assurance; changes in or interpretations of sustainability frameworks, standards and targets, including science-based targets; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and subsequent filings. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.View source version on businesswire.com: https://www.businesswire.com/news/home/20260618316625/en/Investor Relations Contact:
Mary Skafidas

Aptar Named a CDP Supplier Engagement Leader for the Sixth Consecutive YearJune 2, 2026 5:00 PM
Business Wire Recognized for Continued Supply Chain Collaboration AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, was named a CDP Supplier Engagement Leader, for the sixth consecutive year. This assessment, based on information reported within the 2025 CDP reporting cycle, highlights companies that are engaging their suppliers on climate change and supporting efforts to address emissions throughout the value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602301467/en/Aptar is Named a CDP Supplier Engagement Leader for the Sixth Consecutive Year By evaluating supplier engagement and recognizing best practices, CDP aims to accelerate global action on supply chain emissions and the transition towards a more sustainable economy. Aptar received an ‘A’ score on the Supplier Engagement Assessment (SEA), which is in the leadership band. As part of Aptar’s global sustainability strategy, the Company is working to cultivate a supply chain that is both socially inclusive and environmentally conscious, in support of customer and consumer needs. In recent years, Aptar has continued to work with suppliers to support emission-reduction efforts aligned with its validated science-based targets and Carbon Transition Plan. More than 90% of Aptar’s total emissions are Scope 3 emissions, with over 80% of these linked to purchased goods and services, primarily raw materials such as plastics. For this reason, Aptar collaborates with suppliers, particularly those providing raw materials, to identify potential lower-carbon alternatives and advance circularity through product design and material selection. Aptar’s Purchasing teams engage suppliers through both one-on-one collaboration and structured forums such as the Aptar Global Supplier Summit. The 2026 summit further strengthened collaboration through targeted challenge briefs, innovation exchanges, and dedicated working sessions that connected suppliers with Aptar teams to address operational and sustainability priorities. These interactions are designed to support alignment with Aptar’s sustainability strategy while advancing practical, supplier-led solutions. In parallel, Aptar continues to strengthen expectations for supplier performance and transparency. Aptar’s expectations of suppliers include sharing environmental data, participating in assessments and screening programs, and contributing to initiatives focused on materials, emissions reduction, and responsible sourcing. The Supplier Engagement Assessment methodology provides a score which assesses supplier action as reported by a company’s CDP response. The score assesses the level of detail and comprehensiveness of the content, as well as the company’s awareness of climate change issues, management methods and progress towards action taken on climate change as reported in the response. The highest-rated companies are recognized as Supplier Engagement Leaders on the CDP website. For more information on Aptar’s sustainability progress, including its responsible supply chain efforts, visit aptar.com/sustainability. About Aptar Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com. This press release contains forward-looking statements, including statements regarding Aptar’s sustainability strategy, supplier engagement and collaboration, emissions-reduction efforts, science-based targets and Carbon Transition Plan, and related expectations regarding lower-carbon alternatives, circularity, supplier performance and transparency. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues,” “working,” “support,” “advance” and other similar expressions, or future or conditional verbs such as “will,” “should,” “would” and “could,” which are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: supplier participation, performance, transparency and data availability and accuracy; availability, cost and performance of lower-carbon materials, recycled materials and other alternatives; customer and consumer preferences; product performance, quality or supply chain matters; the regulatory environment, including laws, regulations, standards and reporting requirements relating to climate, emissions and sustainability matters; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260602301467/en/ Investor Relations Contact:
Mary Skafidas
mary.skafidas@aptar.com
+1 347 351 6407 Media Contact:
Katie Reardon

Aptar to Participate in Upcoming Investor ConferencesMay 27, 2026 5:00 PM
Business Wire AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it will present at two upcoming investor conferences: Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026. Vanessa Kanu, Executive Vice President and CFO, will present at 12:45 p.m. Eastern Standard Time. Wells Fargo Industrials and Materials Conference in Chicago, IL on Tuesday, June 9, 2026. Vanessa Kanu, Executive Vice President and CFO, will present at 1:45 p.m. Eastern Standard Time. A live audio webcast and presentation materials will be available in the "Investors" section of the Company's website at www.aptar.com. About Aptar Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260527069470/en/ Aptar Investor Relations Contact:
Mary Skafidas
mary.skafidas@aptar.com
+1 347 351 6407 Aptar Media Contact:
Katie Reardon
katie.reardon@aptar.com
1 815 479 5671 Original: Aptar to Participate in Upcoming Investor Conferences

Aptar Reports First Quarter 2026 ResultsApril 30, 2026 5:00 PM
Business Wire
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today reported the following first quarter results for the period ended March 31, 2026, as compared to the corresponding period of the last fiscal year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430601030/en/Aptar Reports First Quarter 2026 Results
First Quarter 2026 Highlights


(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)



Reported sales increased 11% and core sales were flat



Reported net income decreased 8% to $73 million and reported earnings per share decreased 4% to $1.12



Adjusted earnings per share were $1.19, a decrease of 8%, compared to the prior year at constant currency



Adjusted EBITDA margin was 19.2% compared to 20.7% in the prior year



Returned $131 million to shareholders through share repurchases and dividends



Gael Touya named Aptar’s next CEO effective September 1, 2026



“Across the broader Pharma portfolio, we continue to see growing demand in key areas including GLP-1 therapies, biologics, systemic nasal drug delivery, nasal decongestants, ophthalmic dispensing, and active material solutions. As anticipated, first quarter results were impacted by emergency medicine destocking, with comparisons further challenged by the exceptionally strong prior-year quarter for the prescription division. The injectables division delivered another quarter of strong, double-digit growth. Consumer dispensing also contributed positively, with volume growth across Beauty and Closures, supported by robust demand in prestige fragrance and beverage applications,” said Stephan B. Tanda, Aptar President and CEO.


First Quarter Results


For the quarter ended March 31, 2026, reported sales increased 11% to $982.9 million compared to $887.3 million in the prior year period. Core sales were flat compared to the prior year period.




First Quarter Segment Sales Analysis

(Change Over Prior Year)








 






Pharma






Beauty






Closures






Total AptarGroup








Reported Sales Growth






7%






19%






5%






11%








Currency Effects (1)






(7)%






(9)%






(5)%






(8)%








Acquisitions






(1)%






(7)%






0%






(3)%








Core Sales Growth






(1)%






3%






0%






0%











 



(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.







Pharma’s reported sales increased 7% when compared to the prior year period, with a currency contribution of 7%. Excluding acquisitions, core sales declined 1% in the quarter when compared to the prior year period. In the prescription division, sales for dispensing systems declined 10% primarily due to reduced sales in the emergency medicine category, as anticipated, while the pipeline for systemic nasal drug delivery continued to build. Consumer healthcare sales increased 4% on strong nasal decongestant and eye care solutions. Sales in the injectables division increased 20%, mainly driven by growth in demand for elastomeric components used for GLP-1, biologics and antithrombotics. Active material science solutions declined 1% due primarily to lower sales for diabetes test strips and probiotics. Adjusted EBITDA margin was 33.3%, a decrease of 150 basis points, reflecting a less favorable product mix, while royalties continued to positively impact margins.


Beauty’s reported sales increased 19% when compared to the prior year period, driven by a 9% benefit from currency changes and a 7% contribution from acquisitions, with core sales growth of 3%. There was increased demand for fragrance dispensing, as well as hair care and body care applications. Adjusted EBITDA margin was 11.1%, a decline of 100 basis points, due to less favorable product mix, primarily in North America and isolated operational disruptions at a supplier as reported last quarter.


Closures’ reported sales rose 5% from the prior year quarter and core sales were flat, with a 5% currency benefit. While product volumes were up, core sales results were negatively impacted by the pass through of lower resin pricing. Adjusted EBITDA margin was 13.1%, a decline of 270 basis points, primarily due to the previously reported maintenance issues, temporary plant closures as a result of extreme weather in North America and certain investment write offs.


Reported first quarter earnings per share were $1.12 compared to $1.17 reported a year ago. Adjusted earnings per share were $1.19, compared to the prior year period’s adjusted earnings per share of $1.30, including comparable exchange rates. The first quarter reported effective tax rate was 22.4% and the adjusted effective tax rate was 22.6%, compared to the prior year period’s reported and adjusted effective tax rates of 25.8%.


Outlook


Regarding Aptar’s outlook, Tanda stated, “Looking ahead to Q2, excluding destocking in emergency medicine within Pharma, we anticipate a solid quarter with growth across each segment. Outside of the emergency medicine end market, our prescription division is expected to return to healthy growth, and we anticipate growth across a number of pharma end markets mainly due to strength in our injectables and consumer healthcare divisions. We also anticipate a strong quarter for Closures and continued growth in Beauty, particularly in fragrance. Heading into the quarter, we remain mindful of potential supply-chain uncertainties as we continue to operate in a dynamic environment.”


Aptar currently expects adjusted earnings per share for the second quarter of 2026 to be in the range of $1.32 to $1.40. This guidance assumes an effective tax rate range of 22.5% to 24.5%. The earnings per share guidance range is assuming a 1.18 Euro to USD exchange rate.


Cash Dividends and Share Repurchases


As previously announced, Aptar’s Board of Directors approved a quarterly cash dividend of $0.48 per share. The payment date is May 27, 2026, to stockholders of record as of May 6, 2026. During the first quarter, Aptar repurchased 707 thousand shares for $100 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.


Open Conference Call


There will be a conference call held on Friday, May 1, 2026 at 8:00 a.m. Central Time to discuss the company’s first quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.


About Aptar


Aptar is a global leader in drug delivery and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has more than 14,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.


Presentation of Non-GAAP Information


This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities, and other special items. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. For the quarter ended March 31, 2026, “Other special items” include costs incurred related to non-ordinary-course litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving Aptar’s claims of trade-secret misappropriation and contractual breaches and ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar’s ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to “Legal Proceedings” within Note 13 - Commitments and Contingencies within Aptar’s Form 10-K for the year ended December 31, 2025 and subsequent SEC filings for more information. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring, acquisition costs and other special items.


This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; competition, including technological advances; significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries; our ability to successfully implement facility expansions and new facility projects; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs; significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; loss of royalty revenue due to contract expirations; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; our ability to retain key members of management and manage labor costs; work stoppages due to labor disputes; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.




AptarGroup, Inc.




Condensed Consolidated Financial Statements (Unaudited)




(In Thousands, Except Per Share Data)




Consolidated Statements of Income








 



 






Three Months Ended




March 31,








 






2026






 






2025








 






 






 






 








Net Sales






$






982,868






 






 






$






887,305






 








Cost of Sales (exclusive of depreciation and amortization shown below)






 






630,959






 






 






 






550,891






 








Selling, Research & Development and Administrative






 






167,602






 






 






 






155,277






 








Depreciation and Amortization






 






75,725






 






 






 






65,647






 








Restructuring Initiatives






 






1,086






 






 






 






2,042






 








Operating Income






 






107,496






 






 






 






113,448






 








Other Income (Expense):






 






 






 








Interest Expense






 






(16,942






)






 






 






(11,351






)








Interest Income






 






3,642






 






 






 






2,814






 








Net Investment Loss






 






(1,086






)






 






 






(1,096






)








Equity in Results of Affiliates






 






714






 






 






 






2,086






 








Miscellaneous (Expense) Income, net






 






(53






)






 






 






114






 








Income before Income Taxes






 






93,771






 






 






 






106,015






 








Provision for Income Taxes






 






21,004






 






 






 






27,352






 








Net Income






$






72,767






 






 






$






78,663






 








Net (Income) Loss Attributable to Noncontrolling Interests






 






(4






)






 






 






135






 








Net Income Attributable to Redeemable Noncontrolling Interests






 






(89






)






 






 






—






 








Net Income Attributable to AptarGroup, Inc.






$






72,674






 






 






$






78,798






 








Net Income Attributable to AptarGroup, Inc. per Common Share:






 






 






 








Basic






$






1.13






 






 






$






1.19






 








Diluted






$






1.12






 






 






$






1.17






 








 






 






 






 








Average Numbers of Shares Outstanding:






 






 






 








Basic






 






64,050






 






 






 






66,271






 








Diluted






 






64,834






 






 






 






67,491






 









AptarGroup, Inc.




Condensed Consolidated Financial Statements (Unaudited)




(continued)




($ In Thousands)




Consolidated Balance Sheets










 



 






March 31,

2026






 






December 31,

2025








ASSETS






 






 






 








 






 






 






 








Cash and Equivalents






$






222,529







 






$






402,424









Short-term Investments






 






6,948






 






 






 






7,109






 








Accounts and Notes Receivable, Net






 






833,268






 






 






 






803,830






 








Inventories






 






551,482






 






 






 






537,845






 








Prepaid and Other






 






154,045






 






 






 






142,354






 








Total Current Assets






 






1,768,272






 






 






 






1,893,562






 








Property, Plant and Equipment, Net






 






1,660,929






 






 






 






1,676,479






 








Goodwill






 






1,072,560






 






 






 






1,077,898






 








Other Assets






 






596,022






 






 






 






604,780






 








Total Assets






$






5,097,783






 






 






$






5,252,719






 








 






 






 






 








LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY






 






 






 








 






 






 






 








Short-Term Obligations






$






222,166






 






 






$






343,531






 








Accounts Payable, Accrued and Other Liabilities






 






840,867






 






 






 






822,913






 








Total Current Liabilities






 






1,063,033






 






 






 






1,166,444






 








Long-Term Obligations






 






1,143,370






 






 






 






1,139,433






 








Deferred Liabilities and Other






 






217,129






 






 






 






234,617






 








Total Liabilities






 






2,423,532






 






 






 






2,540,494






 








 






 






 






 








Redeemable Noncontrolling Interests






 






26,694






 






 






 






26,244






 








Total Mezzanine Equity






 






26,694






 






 






 






26,244






 








 






 






 






 








AptarGroup, Inc. Stockholders' Equity






 






2,629,495






 






 






 






2,668,096






 








Noncontrolling Interests in Subsidiaries






 






18,062






 






 






 






17,885






 








Total Stockholders' Equity






 






2,647,557






 






 






 






2,685,981






 








 






 






 






 








Total Liabilities, Mezzanine Equity and Stockholders' Equity






$






5,097,783






 






 






$






5,252,719






 









AptarGroup, Inc.




Condensed Consolidated Financial Statements (Unaudited)




(continued)




($ In Thousands)




Consolidated Statement of Cash Flows









 






 






 








Three Months Ended March 31,






2026






 






2025








 






 






 






 








Cash Flows from Operating Activities:






?






 






?








Net income






$






72,767






 






 






$






78,663






 








Adjustments to reconcile net income to net cash provided by operations:






 






 






 








Depreciation






 






64,310






 






 






 






54,903






 








Amortization






 






11,415






 






 






 






10,744






 








Stock-based compensation






 






16,764






 






 






 






19,193






 








Provision for CECL






 






644






 






 






 






35






 








Loss (gain) on disposition of fixed assets






 






81






 






 






 






(271






)








Net loss on remeasurement of equity securities






 






1,086






 






 






 






1,096






 








Deferred income taxes






 






(4,567






)






 






 






(1,860






)








Defined benefit plan expense






 






3,443






 






 






 






3,277






 








Equity in results of affiliates






 






(714






)






 






 






(2,086






)








Impairment loss






 






901






 






 






 






—






 








Changes in balance sheet items, excluding effects from foreign currency adjustments:






 






 






 








Accounts and other receivables






 






(33,030






)






 






 






(69,247






)








Inventories






 






(16,943






)






 






 






(6,043






)








Prepaid and other current assets






 






(12,393






)






 






 






(12,617






)








Accounts payable, accrued and other liabilities






 






36,422






 






 






 






33,324






 








Income taxes payable






 






103






 






 






 






(7,195






)








Retirement and deferred compensation plan






 






(15,271






)






 






 






(11,751






)








Other changes, net






 






(6,324






)






 






 






(7,423






)








Net Cash Provided by Operations






 






118,694






 






 






 






82,742






 








Cash Flows from Investing Activities:






 






 






 








Capital expenditures






 






(65,396






)






 






 






(56,862






)








Proceeds from sale of property, plant and equipment






 






1,327






 






 






 






79






 








Purchases of short-term investments, net






 






(103






)






 






 






(88






)








Acquisition of intangible assets, net






 






(592






)






 






 






(2,475






)








Notes receivable, net






 






(335






)






 






 






2,714






 








Net Cash Used by Investing Activities






 






(65,099






)






 






 






(56,632






)








Cash Flows from Financing Activities:






 






 






 








Proceeds from notes payable and overdrafts






 






2,930






 






 






 






79






 








Repayments of notes payable and overdrafts






 






(2,895






)






 






 






—






 








Proceeds and (repayments) of short term revolving credit facility, net






 






7,000






 






 






 






(23,880






)








Proceeds from long-term obligations






 






5,037






 






 






 






124






 








Repayments of long-term obligations






 






(127,927






)






 






 






(4,552






)








Payment of contingent consideration obligation






 






(2,197






)






 






 






—






 








Dividends paid






 






(30,920






)






 






 






(29,923






)








Proceeds from stock option exercises






 






18,516






 






 






 






3,375






 








Purchase of treasury stock






 






(99,973






)






 






 






(80,000






)








Redeemable noncontrolling interest






 






89






 






 






 






—






 








Net Cash Used by Financing Activities






 






(230,340






)






 






 






(134,777






)








Effect of Exchange Rate Changes on Cash






 






(3,150






)






 






 






10,662






 








Net Decrease in Cash and Equivalents and Restricted Cash






 






(179,895






)






 






 






(98,005






)








Cash and Equivalents and Restricted Cash at Beginning of Period






 






404,849






 






 






 






223,844






 








Cash and Equivalents and Restricted Cash at End of Period






$






224,954






 






 






$






125,839






 









AptarGroup, Inc.




Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)




($ In Thousands)








 



 






Three Months Ended

March 31, 2026








 






Consolidated






 






 






Pharma






 






Beauty






 






Closures






 






Corporate




& Other






 






Net Interest








Net Sales






$






982,868






 






 






 






$






438,560






 






 






$






363,635






 






 






$






180,673






 






 






$






—






 






 






$






—






 








 






 






 






 






 






 






 






 






 






 






 






 






 








Reported net income






$






72,767






 






 






 






 






 






 






 






 






 






 






 






 








Reported income taxes






 






21,004






 






 






 






 






 






 






 






 






 






 






 






 








Reported income before income taxes






 






93,771






 






 






 






 






106,658






 






 






 






14,458






 






 






 






9,184






 






 






 






(23,229






)






 






 






(13,300






)








Adjustments:






 






 






 






 






 






 






 






 






 






 






 






 








Restructuring initiatives






 






1,086






 






 






 






 






5






 






 






 






1,301






 






 






 






249






 






 






 






(469






)






 






 








Net investment loss






 






1,086






 






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






1,086






 






 






 








Transaction costs related to acquisitions






 






45






 






 






 






 






45






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 








Purchase accounting adjustments related to acquisitions and investments






 






145






 






 






 






 






145






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 








Other special items






 






3,727






 






 






 






 






3,727






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 








Adjusted earnings before income taxes






 






99,860






 






 






 






 






110,580






 






 






 






15,759






 






 






 






9,433






 






 






 






(22,612






)






 






 






(13,300






)








Interest expense






 






16,942






 






 






 






 






 






 






 






 






 






 






 






 






16,942






 








Interest income






 






(3,642






)






 






 






 






 






 






 






 






 






 






 






 






(3,642






)








Adjusted earnings before net interest and taxes (Adjusted EBIT)






 






113,160






 






 






 






 






110,580






 






 






 






15,759






 






 






 






9,433






 






 






 






(22,612






)






 






 






—






 








Depreciation and amortization






 






75,725






 






 






 






 






35,643






 






 






 






24,723






 






 






 






14,224






 






 






 






1,135






 






 






 








Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)






$






188,885






 






 






 






$






146,223






 






 






$






40,482






 






 






$






23,657






 






 






$






(21,477






)






 






$






—






 








 






 






 






 






 






 






 






 






 






 






 






 






 








Reported net income margins (Reported net income / Reported Net Sales)






 






7.4






%






 






 






 






 






 






 






 






 






 






 






 








Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)






 






19.2






%






 






 






 






33.3






%






 






 






11.1






%






 






 






13.1






%






 






 






 






 









 






Three Months Ended

March 31, 2025








 






Consolidated






 






 






Pharma






 






Beauty






 






Closures






 






Corporate




& Other






 






Net Interest








Net Sales






$






887,305






 






 






 






$






409,467






 






 






$






305,707






 






 






$






172,131






 






 






$






—






 






 






$






—






 








 






 






 






 






 






 






 






 






 






 






 






 






 








Reported net income






$






78,663






 






 






 






 






 






 






 






 






 






 






 






 








Reported income taxes






 






27,352






 






 






 






 






 






 






 






 






 






 






 






 








Reported income before income taxes






 






106,015






 






 






 






 






111,112






 






 






 






16,681






 






 






 






12,333






 






 






 






(25,574






)






 






 






(8,537






)








Adjustments:






 






 






 






 






 






 






 






 






 






 






 






 








Restructuring initiatives






 






2,042






 






 






 






 






190






 






 






 






395






 






 






 






1,352






 






 






 






105






 






 






 








Net investment loss






 






1,096






 






 






 






 






—






 






 






 






—






 






 






 






—






 






 






 






1,096






 






 






 








Adjusted earnings before income taxes






 






109,153






 






 






 






 






111,302






 






 






 






17,076






 






 






 






13,685






 






 






 






(24,373






)






 






 






(8,537






)








Interest expense






 






11,351






 






 






 






 






 






 






 






 






 






 






 






 






11,351






 








Interest income






 






(2,814






)






 






 






 






 






 






 






 






 






 






 






 






(2,814






)








Adjusted earnings before net interest and taxes (Adjusted EBIT)






 






117,690






 






 






 






 






111,302






 






 






 






17,076






 






 






 






13,685






 






 






 






(24,373






)






 






 






—






 








Depreciation and amortization






 






65,647






 






 






 






 






31,148






 






 






 






20,062






 






 






 






13,575






 






 






 






862






 






 






 






—






 








Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)






$






183,337






 






 






 






$






142,450






 






 






$






37,138






 






 






$






27,260






 






 






$






(23,511






)






 






$






—






 








 






 






 






 






 






 






 






 






 






 






 






 






 








Reported net income margins (Reported net income / Reported Net Sales)






 






8.9






%






 






 






 






 






 






 






 






 






 






 






 








Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)






 






20.7






%






 






 






 






34.8






%






 






 






12.1






%






 






 






15.8






%






 






 






 






 









AptarGroup, Inc.




Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)




(In Thousands, Except Per Share Data)








 



 






Three Months Ended

March 31,








 






2026






 






2025








 






 






 






 








Income before Income Taxes






$






93,771






 






 






$






106,015






 








 






 






 






 








Adjustments:






 






 






 








Restructuring initiatives






 






1,086






 






 






 






2,042






 








Net investment loss






 






1,086






 






 






 






1,096






 








Transaction costs related to acquisitions






 






45






 






 






 






—






 








Purchase accounting adjustments related to acquisitions and investments






 






145






 






 






 






—






 








Other special items






 






3,727






 






 






 






—






 








Foreign currency effects (1)






 






 






 






8,992






 








Adjusted Earnings before Income Taxes






$






99,860






 






 






$






118,145






 








 






 






 






 








Provision for Income Taxes






$






21,004






 






 






$






27,352






 








 






 






 






 








Adjustments:






 






 






 








Restructuring initiatives






 






279






 






 






 






506






 








Net investment loss






 






266






 






 






 






269






 








Transaction costs related to acquisitions






 






11






 






 






 






—






 








Purchase accounting adjustments related to acquisitions and investments






 






49






 






 






 






—






 








Other special items






 






953






 






 






 






—






 








Foreign currency effects (1)






 






 






 






2,320






 








Adjusted Provision for Income Taxes






$






22,562






 






 






$






30,447






 








 






 






 






 








Net (Income) Loss Attributable to Noncontrolling Interests






$






(4






)






 






$






135






 








Net Income Attributable to Redeemable Noncontrolling Interests






$






(89






)






 






$






—






 








 






 






 






 








Net Income Attributable to AptarGroup, Inc.






$






72,674






 






 






$






78,798






 








 






 






 






 








Adjustments:






 






 






 








Restructuring initiatives






 






807






 






 






 






1,536






 








Net investment loss






 






820






 






 






 






827






 








Transaction costs related to acquisitions






 






34






 






 






 






—






 








Purchase accounting adjustments related to acquisitions and investments






 






96






 






 






 






—






 








Other special items






 






2,774






 






 






 






—






 








Foreign currency effects (1)






 






 






 






6,672






 








Adjusted Net Income Attributable to AptarGroup, Inc.






$






77,205






 






 






$






87,833






 








 






 






 






 








Average Number of Diluted Shares Outstanding






 






64,834






 






 






 






67,491






 








 






 






 






 








Net Income Attributable to AptarGroup, Inc. Per Diluted Share






$






1.12






 






 






$






1.17






 








 






 






 






 








Adjustments:






 






 






 








Restructuring initiatives






 






0.01






 






 






 






0.02






 








Net investment loss






 






0.01






 






 






 






0.01






 








Transaction costs related to acquisitions






 






—






 






 






 






—






 








Purchase accounting adjustments related to acquisitions and investments






 






—






 






 






 






—






 








Other special items






 






0.05






 






 






 






—






 








Foreign currency effects (1)






 






 






 






0.10






 








Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share






$






1.19






 






 






$






1.30






 














 



(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.









AptarGroup, Inc.




Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)




(In Thousands)








 



 






Three Months Ended

March 31,








 






2026






 






2025








 






 






 






 








Net Cash Provided by Operations






$






118,694






 






 






$






82,742






 








Capital Expenditures






 






(65,396






)






 






 






(56,862






)








Free Cash Flow






$






53,298






 






 






$






25,880






 









AptarGroup, Inc.




Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)




(In Thousands, Except Per Share Data)








 



 






Three Months Ending

June 30,








 






Expected 2026






 






2025








 






 






 






 








Income before Income Taxes






 






 






$






139,714






 








 






 






 






 








Adjustments:






 






 






 








Restructuring initiatives






 






 






 






1,579






 








Net investment gain






 






 






 






(2,102






)








Transaction costs related to acquisitions






 






 






 






344






 








Foreign currency effects (1)






 






 






 






919






 








Adjusted Earnings before Income Taxes






 






 






$






140,454






 








 






 






 






 








Provision for Income Taxes






 






 






$






27,982






 








 






 






 






 








Adjustments:






 






 






 








Restructuring initiatives






 






 






 






421






 








Net investment gain






 






 






 






(515






)








Transaction costs related to acquisitions






 






 






 






86






 








Foreign currency effects (1)






 






 






 






184






 








Adjusted Provision for Income Taxes






 






 






$






28,158






 








 






 






 






 








Net Income Attributable to Noncontrolling Interests






 






 






$






(12






)








 






 






 






 








Net Income Attributable to AptarGroup, Inc.






 






 






$






111,720






 








 






 






 






 








Adjustments:






 






 






 








Restructuring initiatives






 






 






 






1,158






 








Net investment gain






 






 






 






(1,587






)








Transaction costs related to acquisitions






 






 






 






258






 








Foreign currency effects (1)






 






 






 






735






 








Adjusted Net Income Attributable to AptarGroup, Inc.






 






 






$






112,284






 








 






 






 






 








Average Number of Diluted Shares Outstanding






 






 






 






67,048






 








 






 






 






 








Net Income Attributable to AptarGroup, Inc. Per Diluted Share (3)






 






 






$






1.67






 








 






 






 






 








Adjustments:






 






 






 








Restructuring initiatives






 






 






 






0.02






 








Net investment gain






 






 






 






(0.03






)








Transaction costs related to acquisitions






 






 






 






—






 








Foreign currency effects (1)






 






 






 






0.01






 








Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2)






$1.32 - $1.40






 






$






1.67






 












 



(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency exchange rates.







(2) AptarGroup’s expected adjusted earnings per share range for the second quarter of 2026, see non-GAAP section for full definition, is based on an effective tax rate range of 22.5% to 24.5%. This tax rate range compares to our second quarter of 2025 effective tax rate of 20.0% on both reported and adjusted earnings per share.


 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260430601030/en/
Investor Relations Contact:

Mary Skafidas

mary.skafidas@aptar.com

815-479-5530


Media Contact:

Katie Reardon

katie.reardon@aptar.com

815-479-5671


Original: Aptar Reports First Quarter 2026 Results